Skip to content
AnalystLens

Revolution Medicines 8-K Report, Financial Results (Aug 7, 2024)

Reports
Earnings & Results·Leadership Changes·Exhibits & Filings
Filing Date
Filed August 7, 2024
Period End
August 5, 2024
Securities
RVMDRVMDW
In the record · 2020–202610-K710-Q208-K72

RVMD filed 7 annual reports (10-K), 20 quarterly reports (10-Q) and 72 current reports (8-K) between 2020 and 2026.

  1. Leadership change8-K · Mar ’21Mar ’21
  2. Leadership change8-K · Jul ’22Jul ’22
  3. Deal closed8-K · Nov ’23Nov ’23
  4. Material agreement8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed August 7, 2024. Cited figures are marked; the original filing is the authoritative source.

Revolution Medicines, Inc. reported its financial results for the quarter ended June 30, 2024, and gave an update on corporate progress.

The company reported no revenue for the quarter, compared with $3.8 milliona for the quarter ended June 30, 2023, which it attributed to the termination of its Sanofi collaboration agreement in 2023. Research and development expenses rose to $134.9 million from $98.0 million, and general and administrative expenses rose to $21.7 million from $14.6 million. Net loss was $133.2 million for the quarter, compared with $98.3 million a year earlier, and net loss per share was $0.81.

Cash, cash equivalents and marketable securities totaled $1.59 billionb as of June 30, 2024. The company's clinical focus is RMC-6236, a RAS(ON) multi-selective inhibitor. It plans to start a Phase 3 registrational trial, RASolute 302, in second-line metastatic pancreatic ductal adenocarcinoma this year, following preliminary data showing median PFS of 7.6 months to 8.1 months depending on mutation group.

The company also expects to start a registrational study in previously treated non-small cell lung cancer in the fourth quarter of 2024, and it plans to evaluate RMC-6236 in earlier lines of therapy. Management reiterated 2024 GAAP net loss guidance of $560 million to $600 millionc and stated that current cash can fund planned operations into 2027. Separately, the board increased its size to ten directors and appointed Frank K.

Clyburn, Jr. as an independent Class II director, with a term expiring at the 2025 annual meeting. Mr. Clyburn previously served as CEO of International Flavors & Fragrances and held senior oncology leadership roles at Merck, including leading the Keytruda franchise. He received an option to purchase 27,744 shares and 6,932 restricted stock units under the company's director compensation program.

02—Key points

Key Highlights

  1. Q2 2024 net loss was $133.2 million, or $0.81 per share, versus $98.3 million in Q2 2023.
  2. No revenue was recorded in Q2 2024, compared with $3.8 million in Q2 2023, due to the 2023 termination of the Sanofi collaboration.
  3. R&D expenses rose to $134.9 million from $98.0 million, driven by clinical trial costs for RMC-6236, RMC-6291 and RMC-9805.
  4. Cash, cash equivalents and marketable securities were $1.59 billion as of June 30, 2024.
  5. Company plans to start the Phase 3 RASolute 302 trial of RMC-6236 in second-line metastatic PDAC this year, based on FDA feedback including a 300 mg daily dose.
  6. 2024 GAAP net loss guidance of $560 million to $600 million was reiterated, and current resources are projected to fund operations into 2027.
  7. Frank K. Clyburn, Jr., former CEO of IFF and a former Merck oncology executive, joined the board as an independent director.

03—Questions

Frequently Asked Questions

  1. How much did Revolution Medicines lose in the second quarter of 2024?

    The company reported a net loss of $133.2 million for the quarter ended June 30, 2024, or $0.81 per share, compared with a net loss of $98.3 million for the same quarter of 2023.

  2. Why did revenue decline to zero?

    The company attributed the decrease from $3.8 million in the second quarter of 2023 to zero in the second quarter of 2024 to the termination of its collaboration agreement with Sanofi in 2023.

  3. What are the company's next clinical milestones?

    The company plans to initiate the Phase 3 RASolute 302 trial of RMC-6236 in second-line metastatic pancreatic cancer this year, and expects to start a registrational study in previously treated NSCLC in the fourth quarter of 2024. It also expects to disclose initial clinical data for several combinations and for RMC-9805 in the fourth quarter of 2024.

  4. How long will the company's cash last?

    Based on its current operating plan, the company projects that cash, cash equivalents and marketable securities of $1.59 billion as of June 30, 2024 can fund planned operations into 2027.

  5. Who is the new board member and why was he appointed?

    Frank K. Clyburn, Jr. was appointed as an independent Class II director, with a term expiring at the 2025 annual meeting. He previously served as CEO of International Flavors & Fragrances and held senior oncology roles at Merck, including leading the Keytruda franchise. The company said his experience supports its move into late-stage development and commercial planning for its RAS(ON) inhibitor programs.

04—Continue

← View all 8-K filings